Detailed Information
Cited 0 time in 
Cited 0 time in 
Cited 0 time in
Metadata Downloads
Updated dose escalation results for ReFocus, a first-in-human study of highly selective FGFR2 inhibitor RLY-4008 in cholangiocarcinoma and other solid tumors
- Authors
- Borad, MJ[Borad, Mitesh J.]; Schram, AM[Schram, Alison M.]; Kim, RD[Kim, Richard D.]; Kamath, SD[Kamath, Suneel Deepak]; Sahai, V[Sahai, Vaibhav]; Dotan, E[Dotan, Efrat]; Kelley, RK[Kelley, Robin Kate]; Ponz-Sarvise, M[Ponz-Sarvise, Mariano]; Oh, DY[Oh, Do-Youn]; Yachnin, J[Yachnin, Jeffrey]; Florou, V[Florou, Vaia]; Cassier, PA[Cassier, Philippe Alexandre]; Park, JO[Park, Joon Oh]; Liao, CY[Liao, Chih-Yi]; Millward, M[Millward, Michael]; Ramirez, F[Ramirez, Florence (Tianhui)]; Ricard, FJ[Ricard, Fabien Jean]; Hollebecque, A[Hollebecque, Antoine]; Subbiah, V[Subbiah, Vivek]; Goyal, L[Goyal, Lipika]
- Issue Date
- 1-Jun-2023
- Publisher
- LIPPINCOTT WILLIAMS & WILKINS
- Citation
- JOURNAL OF CLINICAL ONCOLOGY, v.41, no.16
- Indexed
- SCIE
SCOPUS
- Journal Title
- JOURNAL OF CLINICAL ONCOLOGY
- Volume
- 41
- Number
- 16
- ISSN
- 0732-183X
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - Medicine > Department of Medicine > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.